Solid Biosciences LLC (SLDB) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US83422E1055
Solid Biosciences LLC, a biotechnology company listed on NASDAQ as SLDB, focuses on creating treatments for neuromuscular and cardiac conditions in the U.S. Their primary product in development is SGT-003, a cutting-edge gene transfer candidate targeting Duchenne muscular dystrophy. They also work on AVB-202-TT for Friedreich's ataxia, AVB-401 for BAG3-mediated dilated cardiomyopathy, and other solutions for undisclosed heart ailments.
In addition to these therapies, Solid Biosciences LLC works on innovative technologies like dual gene expression and unique capsids that can combine multiple transgenes into a single vector. They have a partnership with Ultragenyx Pharmaceutical Inc. to pioneer new gene therapies for Duchenne, enhancing their impact in the medical industry.
Founded in 2013, Solid Biosciences LLC is headquartered in Charlestown, Massachusetts, and remains dedicated to advancing treatments for various debilitating diseases. For more information, visit their website at https://www.solidbio.com.
Drawdown (Underwater) Chart
SLDB Stock Overview
| Market Cap in USD | 328m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2018-01-26 |
SLDB Stock Ratings
| Growth 5y | -4.80 |
| Fundamental | -63.1 |
| Dividend | - |
| Rel. Performance vs Sector | 5.72 |
| Analysts | 4.30/5 |
| Fair Price Momentum | 9.27 USD |
| Fair Price DCF | - |
SLDB Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
SLDB Growth Ratios
| Growth 12m | 84.02% |
| Growth Correlation 12m | 24% |
| Growth Correlation 3m | 29% |
| CAGR 5y | -42.12% |
| Sharpe Ratio 12m | 0.67 |
| Alpha vs SP500 12m | 60.07 |
| Beta vs SP500 5y weekly | 1.00 |
| ValueRay RSI | 18.29 |
| Volatility GJR Garch 1y | 106.54% |
| Price / SMA 50 | -18.29% |
| Price / SMA 200 | 50.92% |
| Current Volume | 189.9k |
| Average Volume 20d | 189.9k |
External Links for SLDB Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 29, 2024, the stock is trading at USD 8.98 with a total of 189,872 shares traded.
Over the past week, the price has changed by -0.66%, over one month by -32.58%, over three months by +12.81% and over the past year by +84.02%.
According to ValueRays Forecast Model, SLDB Solid Biosciences LLC will be worth about 10.3 in April 2025. The stock is currently trading at 8.98. This means that the stock has a potential upside of +14.59%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 17 | 89.3 |
| Analysts Target Price | 6.8 | -24.8 |
| ValueRay Target Price | 10.3 | 14.6 |